

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application. Any amendments or cancellations to the claims are made without prejudice or disclaimer.

1-44. (Canceled)

45. (Currently Amended) A substantially pure ~~consecutive and~~ anti-angiogenic polypeptide, ~~comprising the central region of human histidine rich glycoprotein (HRGP) corresponding to SEQ.ID.NO:2~~ consisting of SEQ ID NO: 1 or SEQ ID NO: 2.

46. (Currently Amended) The polypeptide of claim 45, ~~consisting of the central region of human histidine rich glycoprotein (HRGP) corresponding to SEQ.ID.NO:2~~ wherein the polypeptide consists of SEQ ID NO: 2.

47. (Currently Amended) ~~A substantially pure consecutive and anti-angiogenic polypeptide, consisting of a subfragment of the central region of human HRGP (SEQ.ID.NO:2)~~ The polypeptide of claim 45, wherein the polypeptide consists of SEQ ID NO: 1.

48-61. (Canceled)

62. (Currently Amended) The polypeptide of ~~claim 47~~ claim 45, wherein said polypeptide is isolated from human HRGP.

63. (Currently Amended) The polypeptide of ~~claim 47~~ claim 45, wherein said polypeptide is isolated from proteolytically processed human HRGP purified from plasma.

64. (Currently Amended) The polypeptide of ~~claim 47~~ claim 45, wherein said polypeptide is recombinantly produced or isolated from recombinantly produced human HRGP.

65. **(Currently Amended)** The polypeptide of ~~claim 47~~ claim 45, wherein said polypeptide is synthetically produced.

66. **(Currently Amended)** The polypeptide of ~~claim 47~~ claim 45, wherein said polypeptide does not promote angiogenesis or does not bind to thrombospondin.

67. **(Currently Amended)** A pharmaceutical composition comprising an effective amount of the polypeptide of ~~claim 47~~ claim 45.

68. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising a pharmaceutically acceptable carrier.

69. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an anti-angiogenic agent.

70. **(Previously Presented)** The pharmaceutical composition of claim 69, wherein said anti-angiogenic agent is selected from the group consisting of angiostatin, thrombostatin, endostatin, interferon- α , interferon-inducible factor 10, and platelet factor 4.

71. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an anti-neoplastic agent.

72. **(Previously Presented)** The pharmaceutical composition of claim 71, wherein said antineoplastic agent is selected from the group consisting of taxol, cyclophosphamide, carboplatinum, cisplatin, cisplatin, gancyclovir, camptothecin, paclitaxel, hydroxyurea, 5-azacytidine, 5-aza-2'-deoxycytidine, and suramin.

73. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an anti-inflammatory agent.

74. **(Previously Presented)** The pharmaceutical composition of claim 73, wherein said antiinflammatory agent is selected from the group consisting of prednisone, a cox-2 inhibitor, ibuprofen and aspirin.

75. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an effective amount of Zn²⁺.

76-83. **(Canceled)**

84. **(New)** A substantially pure anti-angiogenic polypeptide consisting of SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, or SEQ ID NO: 27.

85. **(New)** The substantially pure anti-angiogenic polypeptide of claim 84, wherein the polypeptide consists of SEQ ID NO: 16.

86. **(New)** The substantially pure anti-angiogenic polypeptide of claim 84, wherein the polypeptide consists of SEQ ID NO: 18.

87. **(New)** The substantially pure anti-angiogenic polypeptide of claim 84, wherein the polypeptide consists of SEQ ID NO: 21.

88. **(New)** The substantially pure anti-angiogenic polypeptide of claim 84, wherein the polypeptide consists of SEQ ID NO: 23.

89. **(New)** The substantially pure anti-angiogenic polypeptide of claim 84, wherein the polypeptide consists of SEQ ID NO: 27.

90. **(New)** A pharmaceutical composition comprising an effective amount of the polypeptide of claim 84.

91. **(New)** A method for inhibiting angiogenesis in a mammal, comprising administering the polypeptide of claim 45 to a mammal in need thereof.

92. **(New)** A method for inhibiting angiogenesis in a mammal, comprising administering the polypeptide of claim 84 to a mammal in need thereof.